Aims: Second-generation antipsychotics are an important component in the management of psychiatric conditions but their use can also lead to weight gain, diabetes, and dyslipidemia. Thus, this study aimed to assess the magnitude of metabolic syndrome and its predictors among patients who were on second-generation antipsychotic drugs at six psychiatry Hospitals, in Addis Ababa, Ethiopia, 2019.
Method: This study was conducted using a Multicenter cross-sectional study design. Medical charts of 510 patients on second-generation antipsychotic drugs who were selected by convenience sampling method and complete patients' charts were included in this study. Data was gathered using a checklist from patients' medical charts. To identify the determinants of metabolic syndrome, a logistic regression model was used.
Result: From a total of 510 patients' Medical charts on the second-generation antipsychotic drugs, 270 (52.9%) of them were females and 240 (47.1%) were males. The magnitude of metabolic syndrome among patients receiving second-generation antipsychotic drugs was found to be 88 (17.8%). Age, education, family history of cardiovascular disease, and type of second-generation antipsychotic drugs are found to be significantly associated factors with metabolic syndrome.
Conclusions: Considerable proportion of patients receiving second-generation antipsychotic medications have metabolic syndrome.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1016/j.dsx.2021.102187 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Distribution and correlates of long-acting injectable antipsychotic use among community mental health center patients.
Psychiatry Res
January 2025
South Carolina Department of Mental Health, 220 Executive Dr, Greer, SC 29651, United States; Department of Neuropsychiatry and Behavioral Science, University of South Carolina School of Medicine, 15 Medical Park, Suite 301, Columbia, SC 29203, United States.
Although long-acting injectable antipsychotics (LAIs) are an important pharmaceutical option in the management of schizophrenia and related disorders, little is known about patient characteristics related to LAI use in real-world outpatient settings. We analyzed electronic medical records from 41,401 patients who received psychiatric services from one of 16 regional mental health centers operated by the South Carolina Department of Mental Health in 2022. We compared the use of first- and second-generation LAIs and oral antipsychotics by sociodemographic (age, gender, race/ethnicity, zip code, payment source) and clinical characteristics (psychiatric diagnoses, service use).
View Article and Find Full Text PDFAntipsychotic medication non-adherence and its determinants among out-patients with schizophrenia.
Malawi Med J
January 2025
Nnamdi Azikiwe University Ringgold standard institution - Department of Mental Health, Nnewi Campus, Nnewi, Anambra, Nigeria.
Introduction: While antipsychotics are key requirement in acute and long-term management of schizophrenia, medication adherence remains a major unmet need in its care. This paper assessed the prevalence of oral antipsychotic non-adherence among outpatients with schizophrenia and its associated clinico-demographic factors.
Method: Three hundred and ten adult outpatients (18-64 years of age) were cross-sectionally interviewed after being diagnosed of schizophrenia using ICD-10 criteria, and the diagnosis confirmed with the Mini International Neuropsychiatric Interview (MINI).
Cross-titration from risperidone to clozapine utilizing clozapine serum concentrations: A case report.
Pharmacotherapy
January 2025
Department of Pharmacy Practice, School of Pharmacy, Westbrook College of Health Professions, University of New England, Portland, Maine, USA.
Introduction: Clozapine and risperidone are second-generation antipsychotics used in the treatment of schizophrenia. There are no guidelines on cross-titration of antipsychotics and, additionally, there is a paucity of published data to support the potential utility of using serum drug levels to guide dosing in these situations.
Case Report: A 68-year-old female patient with a history of schizophrenia, taking risperidone and fluoxetine, and a recent diagnosis of Parkinson's disease was admitted to the hospital after a fall at home.
Second-generation antipsychotic-induced dystonia: Analysis using the Japanese Adverse Drug Event Report (JADER) database.
Psychiatry Clin Neurosci
January 2025
Department of Psychiatry, Nagoya University Graduate School of Medicine, Nagoya, Japan.
Aim: This study aimed to explore the comparative risks for dystonia among different second-generation antipsychotics (SGAs), the influence of sex, and the relationship between the time-to-onset of dystonia and its outcomes.
Methods: We analyzed data from the Japanese Adverse Drug Event Report database from April 2004 to November 2023. Cases involving oral SGAs, excluding clozapine, were extracted.
Forty years of research trends in long-acting injectable antipsychotics: A bibliometric analysis.
Australas Psychiatry
January 2025
Pamukkale University Faculty of Medicine, Child and Adolescent Psychiatry Department, Denizli, Türkiye.
Background: Using long-acting injectable (LAI) antipsychotics is crucial for treating psychiatric illnesses, particularly those within the schizophrenia spectrum. Through bibliometric analysis, our study aimed to provide an understanding of the changes in research trends related to LAIs over the past 40 years.
Methods: We collected the publications from 1983 to 2023 related to research studies on LAIs included in the Web of Science database.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!